CURRICULUM VITAE

RENATA GONTIJO LIMA
Phone number: 248 574-1978.
E-mail: renata_gontijo@hotmail.com

I. Education:

Master of Science in Pharmaceutical Medicine by Hibernia College
2013 – 2015
- Thesis: Educational Grants by Pharmaceutical Companies: Physician and Corporate Views - May2015
- Certificate in Pharmaceutical Research and Development by Hibernia College - Feb2014
- Leadership & Negotiation Course at Harvard University - June2014
- Certificate in Medical Affairs by Hibernia College - July2014

Post-Graduation *Stricto Sensu* – Master's Degree
2003 – 2006: *Universidade de São Paulo* (USP), Brazil
- Thesis: Prevalence of Asthma, Rhinitis and Atopic Eczema in schoolchildren from 6 to 7 years old in the west area of the city of São Paulo using the standard questionnaire of the "International Study of Asthma and Allergies in Childhood" (ISAAC) – Phase IIIB

Specialized Medical Training
- 1998 - 2000: Fellowship in Pediatrics at the Pediatrics Department from *Universidade de São Paulo* (*Instituto da Criança* – FMUSP), Brazil
- 2000 - 2002: Fellowship in Allergy and Immunology at the Pediatrics Department from *Universidade de São Paulo* (*Instituto da Criança* – FMUSP), Brazil
- Title of Specialist in Pediatrics by Brazilian Society of Pediatrics in 2000
- Title of Specialist in Allergy and Immunology by Brazilian Association of Allergy and Immunology in 2002

Graduation
1992 - 1997: Medical Degree by *Universidade Federal do Pará (UFPA*), Brazil.

Languages
English (Fluent), Spanish (Advanced) and Portuguese (Mother tongue)

II. Professional Experience

1. Associate Vice President, Global Development for Immunology, focus on Allergy and Dermatology at Eli Lilly from June 2022 to date

2. Global Development Sr. Medical Director for Late Phase Immunology and Dermatology at Eli Lilly from November 2018 to May 2022

2. Franchise Lead Clinical Research Medical Director (CRMD) at Novartis U.S.A
- Franchise Lead CRMD for Neuroscience, Immunology and Dermatology at Novartis from May 2016 to November 2018
- TA Lead CRMD for Neuroscience and Respiratory from February to November 2018
- Opportunity to lead 3 different teams of CRMDs: 4 CRMDs dedicated to the medical management of I&D clinical studies, 4 CRMDs dedicated to Neuroscience and 2 CRMDs supporting Respiratory studies.
- Plan, direct and coordinate the operations of CRMDs for NS and I&D/ NS and Resp
- Provide coach for CRMDs on their daily activities: protocol feasibility, physician to physician contact, protocol training, medical issue/question management, safety review and local regulatory interaction, strategic medical input into protocol design at a global level, clinical site selection

3. Clinical Research Medical Director (CRMD), Immunology and Dermatology (I&D) at Novartis U.S.A: July 2015 to May 2016
- Point of contact for medical feasibility assessments of global protocols, providing feedback to the global team regarding the required population, study design, inclusion/ exclusion criteria, competitive landscape, according to the U.S. medical practice and feedback from local investigators/ medical experts
- Responsible for providing medical monitoring to clinical sites working on I&D global studies
- Close collaboration with MSLs, medical affairs team and global teams for Dermatology, Rheumatology, Immunology, Transplantation and Hepatology clinical studies

4. Clinical Research Medical Advisor (CRMA)/ Senior Medical Manager at Novartis Brazil: Apr2012 to Aug2014
- Recognized for stablishing the CRMA role in Brazil with excellence and for sharing best practices with Latin American counterparts
- Responsible for providing a high level of medical expertise to achieve Novartis' objectives in the area of Clinical Drug Development.
- Country primary medical responsible for international clinical research, including protocol feasibility, physician to physician contact, protocol training, medical issue/question management, safety review and local regulatory interaction.
- Provided strategic medical input into protocol design at a global level when needed and cooperated with Medical Affairs colleagues to identify/involve investigators and key opinion leaders in order to exploit the value of the assigned project(s) in the contest of the investigational product(s).

5. Senior Medical Advisor at Janssen-Cilag Brazil: May2008 to Aug2011
- Lead of Medical affairs and clinical development for Immunology, Cardiology and Transplant therapeutical areas
- Products: Tacrolimus (Prograf), Nesiritide (Natrecor), Ustekinumab (Stelara)
- Launching of Natrecor, Prograf XL and Stelara in Brazil
- Latin America medical lead for Ustekinumab
- Medical support for marketing, regulatory and pharmacoeconomics areas
- Medical responsible for local clinical research, including first approval of studies of investigator's initiative
- Medical support for international clinical studies
- People management: two medical managers (supporting the cardiology and transplant areas), and one medical scientific liaison (supporting Stelara)

6. Medical Advisor at Abbott Laboratories Brazil: Sep2006 to Apr2008
- Medical lead for Cardiovascular therapeutical area at Abbott Brazil: *Simdax, Ritmonorm, Blopress, Venocur*
- Responsible for products with pediatric indications at the Immunology therapeutical area: *Synagis and Survanta*
- Interactions with national and international medical experts from different medical backgrounds: Cardiology, Vascular Surgery, Pediatrics, Infectious Disease, Vaccines, Neonatology, Allergy and Immunology.
- Medical support for marketing, regulatory and Pharmacoeconomics areas
- Medical responsible for local clinical research, including first approval of studies of investigator's initiative

7. Medical Scientific Liaison – Novartis Brazil: Nov2005 to Sep2006
- First physician on this position at the pharmaceutical segment in Brazil
- Creation of local MSL processes, identification of medical experts on respiratory area
- Supported launching of Omalizumab (Xolair) in Brazil: responsible for medical interactions with Asthma and COPD medical experts and data dissemination activities
- Medical support for local clinical research
- Local medical person liable for Novartis pipeline information as well as new molecules in development for Respiratory diseases, Allergy and Immunology.

8. Pediatrician at *Hospital Regional da Secretaria Estadual de Saúde de São Paulo*: Sep2002 to Feb2008

9. Pediatrician at *Autarquia Hospitalar Municipal Regional Central – Hospital Menino Jesus*: May2003 to Nov2005

10. Pediatrician at *Irmandade de Santa Casa de Misericórdia de São Paulo – Hospital Geral de Guarulhos*: Oct2001 to Nov2005

11**.** Pediatrician at Emergency Room from *Clínica Infantil do Ipiranga*: Aug2000 to Apr2003

12. Pediatrician at *Instituto da Criança (ICr)/ Hospital das Clínicas – Universidade de São Paulo* (Feb2000 to July2006), Brazil:
- Assistant: outpatient and inpatient care of children with primary immunodeficiency and allergic diseases such as asthma, rhinitis, atopic dermatitis and food allergy.
- Teaching: supervision and training of medical fellowships in pediatrics, allergy and immunology
- Research: responsible for the Clinical Trials of Pediatric Allergy and Immunology as sub-investigator

III. Publications

1. Lima RG, Pastorino AC, Casagrande RR, Sole D, Leone C, Jacob CM. Prevalence of asthma, rhinitis and eczema in 6 - 7 years old students from the western districts of São Paulo City, using the standardized questionnaire of the "International Study of Asthma and Allergies in Childhood" (ISAAC)-phase IIIB. Clinics (Sao Paulo). 2007 Jun;62(3):225-34.

2. Casagrande RR, Pastorino AC, Souza RG, Leone C, Solé D, Jacob CM. Asthma prevalence and risk factors in schoolchildren of the city of São Paulo, Brazil. Rev Saude Publica. 2008 Jun;42(3):517-23.

3. Pastorino AC, Kuschnir FC, Arruda LK, Casagrande RR, de Souza RG, Dias GA, Silveira HH, da Cunha AJ, Jacob CM, Solé D. Sensitisation to aeroallergens in Brazilian adolescents living at the periphery of large subtropical urban centres Allergol Immunopathol (Madr). 2008 Jan-Feb;36(1):9-16.

4. Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020 Jun;182(6):1348-1358.

5. A S Paller, M M B Seyger, G Alejandro Magariños, J Bagel, A Pinter, J Cather, S Keller, C Rodriguez Capriles, R Gontijo Lima, G Gallo, C A Little, E Edson-Heredia, L Li, W Xu, K Papp, IXORA-PEDS study group. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol 2020 Aug;183(2):231-241

6. Blauvelt A, Leonardi C, Elewski B, Crowley JJ, Guenther LC, Gooderham M, Langley RG, Vender R, Pinter A, Griffiths CEM, Tada Y, Elmaraghy H, Lima RG, Gallo G, Renda L, Burge R, Park SY, Zhu B, Papp K; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Br J Dermatol. 2021 Jun;184(6):1047-1058

7. Eric L. Simpson, MD; Melinda Gooderham, MD; Andreas Wollenberg, MD; Stephan Weidinger, MD, PhD; April Armstrong, MD, MPH; Jennifer Soung, MD; Silvia Ferrucci, MD; Renata Gontijo Lima, MD; Michael M. Witte, PhD; Wen Xu, PhD; Hany ElMaraghy, MD; Chitra R. Natalie, MD; Evangeline Pierce, PhD; Andrew Blauvelt, MD, MBA; for the ADhere Investigators. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial (ADhere). JAMA Dermatol. 2023;159(2):182-191

8. Amy S. Paller, Carsten Flohr, Lawrence F. Eichenfield, Alan D. Irvine, Jamie Weisman, Jennifer Soung, Ana Pinto Correia, Chitra R. Natalie, Claudia Rodriguez Capriles, Evangeline Pierce, Sarah Reifeis, Renata Gontijo Lima, Clara Armengol Tubau, Vivian Laquer & Stephan Weidinger. Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study. Dermatol Ther (Heidelb) (2023). https://doi.org/10.1007/s13555-023-00942-y

9. Jonathan I. Silverberg, M.D., Ph.D., M.P.H, Emma Guttman-Yassky, M.D., Ph.D., Diamant Thaçi, M.D., Alan D. Irvine, M.D., Linda Stein Gold, M.D., Andrew Blauvelt, M.D., Eric L. Simpson, M.D., Chia-Yu Chu, M.D., Ph.D., Zhuqing Liu, Ph.D., Renata Gontijo Lima, M.D., Sreekumar G. Pillai, Ph.D., and Julien Seneschal, M.D., Ph.D. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med 2023; 388:1080-1091

10. Silverberg JI, Guttman-Yassky E, Gontijo Lima R. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. Reply. N Engl J Med. 2023 Jun 15;388(24):2299-2300.